

Massimo Puoti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8750269/massimo-puoti-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

217 papers	10,951 citations	47 h-index	101 g-index
233 ext. papers	12,786 ext. citations	6 avg, IF	5.85 L-index

#	Paper	IF	Citations
217	Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination: A pivotal study in Italy.. <i>Liver International</i> , 2022 ,	7.9	0
216	A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort.. <i>Hepatology</i> , 2021 ,	11.2	3
215	HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofaa566	1	0
214	Neurological manifestations in patients hospitalized with COVID-19: A retrospective analysis from a large cohort in Northern Italy. <i>European Journal of Neuroscience</i> , 2021 , 53, 2912-2922	3.5	9
213	Algorithm for Individual Prediction of COVID-19-Related Hospitalization Based on Symptoms: Development and Implementation Study. <i>JMIR Public Health and Surveillance</i> , 2021 , 7, e29504	11.4	0
212	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021 , 53, 1603-1609	3.3	
211	Frontline Screening for SARS-CoV-2 Infection at Emergency Department Admission by Third Generation Rapid Antigen Test: Can We Spare RT-qPCR?. <i>Viruses</i> , 2021 , 13,	6.2	10
210	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. <i>Digestive and Liver Disease</i> , 2021 , 53, 677-681	3.3	7
209	Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. <i>Digestive and Liver Disease</i> , 2021 , 53, 612-619	3.3	3
208	Nasopharyngeal SARS-CoV-2 Load at Hospital Admission as a Predictor of Mortality. <i>Clinical Infectious Diseases</i> , 2021 , 72, 1868-1869	11.6	9
207	High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 558-568	3.4	0
206	Impact of immunosuppressive therapy on the severity of COVID-19 in solid organ transplant recipients. <i>Journal of Infection</i> , 2021 , 82, 414-451	18.9	3
205	Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 105-111	9.5	41
204	Does interval time between liver transplant and COVID-19 infection make the difference?. <i>Digestive and Liver Disease</i> , 2021 , 53, 169-170	3.3	3
203	Vaccinations in patients with multiple sclerosis: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 347-359	5	24
202	The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: A Delphi consensus statement. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 331-346	5	16
201	Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy. <i>Nature Communications</i> , 2021 , 12, 434	17.4	44

200	Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. <i>PLoS ONE</i> , 2021 , 16, e0247275	3.7	2
199	SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study. <i>BMC Infectious Diseases</i> , 2021 , 21, 184	4	14
198	Home-based COVID 19 management: A consensus document from Italian general medical practitioners and hospital consultants in the Lombardy region (Italy). <i>European Journal of Internal Medicine</i> , 2021 , 84, 94-96	3.9	3
197	Reply to: Epidemiological evidence for an association between higher influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy. <i>Journal of Medical Virology</i> , 2021 , 93, 2600-2601	19.7	0
196	Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe-short- And long-term Immune reSponSe evAluationN in health Care workErs. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2966-2979	6.4	6
195	Mild Course of SARS-CoV-2 Infection in a Liver Transplant Recipient Undergoing Plasma Exchange and Defibrotide for Acute Graft Rejection. <i>Transplantation</i> , 2021 , 105, e22-e24	1.8	0
194	Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. <i>Liver Transplantation</i> , 2020 , 26, 1543-1544	4.5	4
193	Anti-NMDA receptor encephalitis in a psychiatric Covid-19 patient: A case report. <i>Brain, Behavior, and Immunity</i> , 2020 , 87, 179-181	16.6	78
192	Clinical outcome in solid organ transplant recipients with COVID-19: A single-center experience. <i>American Journal of Transplantation</i> , 2020 , 20, 2628-2629	8.7	28
191	Persistent positivity and fluctuations of SARS-CoV-2 RNA in clinically-recovered COVID-19 patients. <i>Journal of Infection</i> , 2020 , 81, e90-e92	18.9	46
190	Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2544-2553.e6	6.9	6
189	Optimization of hepatitis C virus screening strategies by birth cohort in Italy. <i>Liver International</i> , 2020 , 40, 1545-1555	7.9	19
188	Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort. <i>Liver International</i> , 2020 , 40, 769-777	7.9	11
187	Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepalICONA foundation cohorts. <i>Digestive and Liver Disease</i> , 2020 , 52, 447-451	3.3	1
186	Successful recovery from severe COVID-19 pneumonia after kidney transplantation: The interplay between immunosuppression and novel therapy including tocilizumab. <i>Transplant Infectious Disease</i> , 2020 , 22, e13334	2.7	17
185	Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials. <i>Liver International</i> , 2020 , 40, 778-786	7.9	13
184	Orthopedic injuries in patients with multiple injuries: Results of the 11th trauma update international consensus conference Milan, December 11, 2017. <i>Journal of Trauma and Acute Care Surgery</i> , 2020 , 88, e53-e76	3.3	8
183	Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. <i>Digestive and Liver Disease</i> , 2020 , 52, 190-198	3.3	6

182	Heart-Kidney Transplanted patient affected by COVID-19 pneumonia treated with tocilizumab on top of immunosuppressive maintenance therapy. <i>IJC Heart and Vasculature</i> , 2020 , 29, 100596	2.4	4
181	Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis. <i>Journal of Infection</i> , 2020 , 81, e11-e17	18.9	70
180	Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3349-3358	5.1	7
179	Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study). <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1545-1553	9.5	43
178	Quantification of 1,3-β-D-glucan by Wako β-glucan assay for rapid exclusion of invasive fungal infections in critical patients: A diagnostic test accuracy study. <i>Mycoses</i> , 2020 , 63, 1299-1310	5.2	5
177	2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. <i>HIV Medicine</i> , 2020 , 21, 617-624	2.7	46
176	EASL recommendations on treatment of hepatitis C: Final update of the series. <i>Journal of Hepatology</i> , 2020 , 73, 1170-1218	13.4	237
175	Detection and quantification of SARS-CoV-2 by droplet digital PCR in real-time PCR negative nasopharyngeal swabs from suspected COVID-19 patients. <i>PLoS ONE</i> , 2020 , 15, e0236311	3.7	65
174	Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study). <i>Expert Review of Anti-Infective Therapy</i> , 2020 , 18, 1271-1279	5.5	13
173	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020 , 14, 362-372	8.8	5
172	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. <i>BMC Public Health</i> , 2019 , 19, 1291	4.1	3
171	Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. <i>Scientific Reports</i> , 2019 , 9, 585	4.9	6
170	Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019 , 38, 1857-1865	5.3	2
169	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 1224-1228	3.4	6
168	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. <i>Journal of Hepatology</i> , 2019 , 71, 397-408	13.4	163
167	The impact of HIV infection and men who have sex with men status on hepatitis A infection: The experience of two tertiary centres in Northern Italy during the 2017 outbreak and in the 2009-2016 period. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 761-765	3.4	5
166	HIV-positive to HIV-positive liver transplantation: To be continued. <i>Journal of Hepatology</i> , 2019 , 70, 788-792	13.4	9
165	Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. <i>Journal of Hepatology</i> , 2019 , 71, 1106-1115	13.4	36

164	Risk factors for community-acquired bacterial meningitis: men who have sex with men (MSM) as a population at risk for meningococcal nasopharyngeal carriage. <i>Infectious Diseases</i> , 2019 , 51, 714-717	3.1	0
163	Sustained virological response with 16-week glecaprevir/pibrentasvir after failure to sofosbuvir/velpatasvir in post-transplant severe HCV recurrence in HIV. <i>Transplant Infectious Disease</i> , 2019 , 21, e13165	2.7	4
162	Italian consensus recommendations for the management of hepatitis C infection in patients with rheumatoid arthritis. <i>Modern Rheumatology</i> , 2019 , 29, 895-902	3.3	7
161	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 117-128	5.38	5
160	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet, The</i> , 2019 , 393, 143-155	4.0	175
159	Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2019 , 70, 379-387	13.4	87
158	AISF position paper on HCV in immunocompromised patients. <i>Digestive and Liver Disease</i> , 2019 , 51, 10-23	3.3	4
157	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Infection</i> , 2019 , 47, 141-168	5.8	
156	Single-center outbreak of <i>Pneumocystis jirovecii</i> pneumonia in heart transplant recipients. <i>Transplant Infectious Disease</i> , 2018 , 20, e12880	2.7	11
155	Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. <i>HIV Clinical Trials</i> , 2018 , 19, 52-60		4
154	EASL Recommendations on Treatment of Hepatitis C 2018. <i>Journal of Hepatology</i> , 2018 , 69, 461-511	13.4	1079
153	Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. <i>New England Journal of Medicine</i> , 2018 , 378, 354-369	59.2	281
152	Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018 , 37, 871-881	5.3	2
151	High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. <i>Journal of Hepatology</i> , 2018 , 69, 293-300	13.4	90
150	Bacterial pneumonia in patients with liver cirrhosis, with or without HIV co-infection: a possible definition of antibiotic prophylaxis associated pneumonia (APAP). <i>Infectious Diseases</i> , 2018 , 50, 125-132	3.1	2
149	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018 , 68, 597-600	13.4	23
148	Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. <i>Scientific Reports</i> , 2018 , 8, 8988	4.9	30
147	Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?. <i>Liver International</i> , 2018 , 38, 2190-2198	7.9	23

146	HIV-1 co-receptor tropism and liver fibrosis in HIV-infected patients. <i>PLoS ONE</i> , 2018 , 13, e0190302	3.7	4
145	Trend of estimated glomerular filtration rate during ombitasvir/paritaprevir/ritonavir plus dasabuvir + ribavirin in HIV/HCV co-infected patients. <i>PLoS ONE</i> , 2018 , 13, e0192627	3.7	5
144	Prise en charge de l'infection par le virus de l'hépatite B chez les patients atteints de polyarthrite rhumatoïde: conférence de consensus italienne. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2018 , 85, 115-120	2.1	1
143	Current and future challenges in HCV: insights from an Italian experts panel. <i>Infection</i> , 2018 , 46, 147-163	5.8	3
142	Treatment of acute hepatitis C: recommendations from an expert panel of the Italian Society of Infectious and Tropical Diseases. <i>Infection</i> , 2018 , 46, 183-188	5.8	5
141	Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject. <i>Aids</i> , 2018 , 32, 1727-1729	3.5	1
140	Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy248	1	4
139	Management of hepatitis C positive patients undergoing active treatment for malignancies: A position paper from the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Malattie Infettive e Tropicali (SIMIT). <i>Seminars in Oncology</i> , 2018 , 45, 259-263	5.5	2
138	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Internal and Emergency Medicine</i> , 2018 , 13, 1139-1145	3.7	2
137	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Internal and Emergency Medicine</i> , 2018 , 13, 695-712	4.8	3
136	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <i>Digestive and Liver Disease</i> , 2018 , 50, 1133-1152	3.3	2
135	Phyllanthus niruri versus Placebo for Chronic Hepatitis B Virus Infection: A Randomized Controlled Trial. <i>Complementary Medicine Research</i> , 2018 , 25, 376-382	1.3	4
134	Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 1949-1954	5.1	14
133	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018 , 46, 607-615	5.8	7
132	Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. <i>Liver International</i> , 2017 , 37, 514-528	7.9	71
131	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017 , 49, 731-741	3.3	14
130	Electrophysiological Adverse Effects of Direct-Acting Antivirals in Patients With Chronic Hepatitis C. <i>Journal of Clinical Pharmacology</i> , 2017 , 57, 931-932	2.9	
129	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017 , 84, 525-530	2.9	12

128	ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. <i>Journal of Hepatology</i> , 2017 , 67, 585-602	13.4	57
127	Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens. <i>PLoS ONE</i> , 2017 , 12, e0177352	3.7	11
126	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. <i>PLoS ONE</i> , 2017 , 12, e0177402	3.7	14
125	Modeling cost-effectiveness and health gains of a "universal" versus "prioritized" hepatitis C virus treatment policy in a real-life cohort. <i>Hepatology</i> , 2017 , 66, 1814-1825	11.2	18
124	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017 , 2, 427-434	18.8	13
123	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017 , 75, 465-471	3.1	3
122	Successful Pre- and Posttransplant Sofosbuvir-Based Anti-Hepatitis C Virus Treatment in Persons Living With Human Immunodeficiency Virus Infection. <i>Open Forum Infectious Diseases</i> , 2017 , 4, ofx065	1	6
121	Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study. <i>PLoS ONE</i> , 2017 , 12, e0172159	3.7	31
120	Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. <i>Clinical Infectious Diseases</i> , 2017 , 64, 680-683	11.6	7
119	Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1405-1411	11.6	78
118	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2663-9	5.1	9
117	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016 , 48, 995-1005	3.3	12
116	Reduced raltegravir clearance in HIV-infected liver transplant recipients: an unexpected interaction with immunosuppressive therapy?. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1341-5	5.1	4
115	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1352-60	5.1	3
114	Nucleos(t)ide Analogue Based Therapy and Management of Patients. <i>Molecular and Translational Medicine</i> , 2016 , 339-359	0.4	
113	HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection. <i>Clinical and Experimental Gastroenterology</i> , 2016 , 9, 351-363	3.1	3
112	Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection. <i>Arthritis Care and Research</i> , 2016 , 68, 738-43	4.7	35
111	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. <i>Clinical Infectious Diseases</i> , 2016 , 63, 1245-1253	11.6	15

110	Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. <i>Journal of Infectious Diseases</i> , 2015 , 212, 367-77	7	46
109	Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. <i>Journal of Women's Health</i> , 2015 , 24, 159-64	3	
108	Point-of-care screening, prevalence, and risk factors for hepatitis B infection among 3,728 mainly undocumented migrants from non-EU countries in northern Italy. <i>Journal of Travel Medicine</i> , 2015 , 22, 78-86	12.9	29
107	Reply to "Debilitating fatigue as a treatment indication in chronic hepatitis C". <i>Journal of Hepatology</i> , 2015 , 63, 1535-6	13.4	3
106	Liver fibrosis, microbial translocation and immune activation markers in HIV and HCV infections and in HIV/HCV co-infection. <i>Digestive and Liver Disease</i> , 2015 , 47, 218-25	3.3	23
105	Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. <i>Journal of Infectious Diseases</i> , 2015 , 211, 178-86	7	114
104	Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. <i>Journal of Hepatology</i> , 2015 , 62, 234-7	13.4	55
103	Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study. <i>Antiviral Therapy</i> , 2015 , 20, 39-48	1.6	1
102	OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy. <i>Liver International</i> , 2015 , 35, 120-9	7.9	4
101	Triple therapy with boceprevir or telaprevir in a European cohort of cirrhotic HIV/HCV genotype 1-coinfected patients. <i>Liver International</i> , 2015 , 35, 2090-9	7.9	10
100	Beyond cure: preventing and managing the complications of end-stage liver disease. <i>Current Opinion in HIV and AIDS</i> , 2015 , 10, 355-60	4.2	1
99	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. <i>PLoS ONE</i> , 2015 , 10, e0140877	3.7	7
98	Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. <i>Lancet, The</i> , 2015 , 385, 1098-106	40	144
97	Understanding the Mechanisms of Fibrogenesis in HIV/HCV-Coinfected Patients: Implications for Clinical Practice. <i>AIDS Reviews</i> , 2015 , 17, 159-70	1.5	3
96	Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. <i>BMC Infectious Diseases</i> , 2014 , 14, 79	4	19
95	Predictive value of FIB-4 and APRI versus METAVIR on sustained virologic response in genotype 1 hepatitis C patients. <i>Hepatology International</i> , 2014 , 8, 83-93	8.8	6
94	Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. <i>New England Journal of Medicine</i> , 2014 , 370, 1889-98	59.2	1402
93	Management of infections pre- and post-liver transplantation: report of an AISF consensus conference. <i>Journal of Hepatology</i> , 2014 , 60, 1075-89	13.4	56

92	Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort. <i>HIV Clinical Trials</i> , 2014 , 15, 151-60		9
91	Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF). <i>Digestive and Liver Disease</i> , 2014 , 46, 18-24	3.3	9
90	OPERA: use of pegylated interferon plus ribavirin for treating HCV-HIV coinfection in interferon-naïve patients. <i>Antiviral Therapy</i> , 2014 , 19, 735-45	1.6	5
89	Efficacy of sofosbuvir-based therapies in HIV/HCV infected patients and persons who inject drugs. <i>Digestive and Liver Disease</i> , 2014 , 46 Suppl 5, S206-11	3.3	6
88	Management of infections in cirrhotic patients: report of a consensus conference. <i>Digestive and Liver Disease</i> , 2014 , 46, 204-12	3.3	36
87	Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy. <i>Antiviral Therapy</i> , 2014 , 19, 407-14	1.6	5
86	Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy. <i>BMC Research Notes</i> , 2013 , 6, 153	2.3	2
85	Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. <i>Journal of Hepatology</i> , 2013 , 58, 792-800	13.4	88
84	Chronic hepatitis C in Italy: the vanishing of the first and most consistent epidemic wave. <i>Digestive and Liver Disease</i> , 2013 , 45, 369-70	3.3	10
83	Optimizing treatment in HIV/HCV coinfection. <i>Digestive and Liver Disease</i> , 2013 , 45 Suppl 5, S355-62	3.3	10
82	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , 2013 , 27, 2707-14	3.5	12
81	Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: a case-control study. <i>Scandinavian Journal of Infectious Diseases</i> , 2012 , 44, 879-83		1
80	High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHECY cohort confirm results from randomized clinical trials. <i>Hepatology</i> , 2012 , 56, 2039-50	11.2	83
79	Rhinoscleroma in an immigrant from Egypt: a case report. <i>Journal of Travel Medicine</i> , 2012 , 19, 387-90	12.9	7
78	Top topics in HCV research arena. <i>BMC Infectious Diseases</i> , 2012 , 12 Suppl 2, S7	4	2
77	The burden of liver disease in human immunodeficiency virus-infected patients. <i>Seminars in Liver Disease</i> , 2012 , 32, 103-13	7.3	68
76	Circulating sCD14 is associated with virological response to pegylated-interferon-alpha/ribavirin treatment in HIV/HCV co-infected patients. <i>PLoS ONE</i> , 2012 , 7, e32028	3.7	30
75	Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. <i>Digestive and Liver Disease</i> , 2011 , 43, 259-65	3.3	25

74	The epidemiological pattern of chronic liver diseases in a community undergoing voluntary screening for hepatitis B and C. <i>Digestive and Liver Disease</i> , 2011 , 43, 653-8	3.3	12
73	Hepatocellular carcinoma in HIV hepatitis C virus. <i>Current Opinion in HIV and AIDS</i> , 2011 , 6, 534-8	4.2	14
72	Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study. <i>Antiviral Therapy</i> , 2011 , 16, 667-75	1.6	15
71	The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. <i>Liver International</i> , 2011 , 31, 66-74	7.9	28
70	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. <i>Liver International</i> , 2011 , 31 Suppl 2, 30-60	7.9	293
69	Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. <i>Autoimmunity Reviews</i> , 2011 , 10, 444-54	13.6	165
68	Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis. <i>Gut</i> , 2011 , 60, 1023	19.2	9
67	Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , 2010 , 24, 857-65	3.5	47
66	HIV-related liver disease: ARV drugs, coinfection, and other risk factors. <i>Journal of the International Association of Providers of AIDS Care</i> , 2009 , 8, 30-42		19
65	Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. <i>Journal of Rheumatology</i> , 2009 , 36, 1188-94	4.1	61
64	Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. Authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 216-216	5.1	
63	Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 51, 574-81	3.1	22
62	Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 575-8	5.1	9
61	Risk of developing specific AIDS-defining illnesses in patients coinfecting with HIV and hepatitis C virus with or without liver cirrhosis. <i>Clinical Infectious Diseases</i> , 2009 , 49, 612-22	11.6	47
60	Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. <i>Aids</i> , 2008 , 22, 1399-410	3.5	122
59	Opportunistic disease and mortality in patients coinfecting with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1468-75	11.6	48
58	Hepatitis B virus and HIV coinfection in low-income countries: unmet needs. <i>Clinical Infectious Diseases</i> , 2008 , 46, 367-9	11.6	21
57	Insulin resistance impairs rapid virologic response in HIV/hepatitis C virus coinfecting patients on peginterferon-alfa-2a. <i>Aids</i> , 2008 , 22, 857-61	3.5	31

56	Pathogenesis of liver damage in HCV-HIV patients. <i>AIDS Reviews</i> , 2008 , 10, 15-24	1.5	11
55	HIV Coinfection and Antiretroviral Therapy Enhances Liver Steatosis in Patients with Hepatitis C, but Only in those Infected by HCV Genotype other than 3. <i>Antiviral Therapy</i> , 2008 , 13, 1057-1065	1.6	11
54	Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients. <i>Drug Safety</i> , 2007 , 30, 1161-9	5.1	15
53	Impact of hepatitis C virus infection on lifestyle. <i>World Journal of Gastroenterology</i> , 2007 , 13, 2722-6	5.6	10
52	Care of patients coinfectd with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. <i>Aids</i> , 2007 , 21, 1073-89	3.5	250
51	Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?. <i>Aids</i> , 2007 , 21, 599-606	3.5	30
50	Is the CD4 cell percentage a better marker of immunosuppression than the absolute CD4 cell count in HIV-infected patients with cirrhosis?. <i>Clinical Infectious Diseases</i> , 2007 , 45, 650-3	11.6	6
49	The burden of HIV and hepatitis C virus coinfection. <i>Current Opinion in HIV and AIDS</i> , 2007 , 2, 460-5	4.2	10
48	Natural history of compensated viral cirrhosis in a cohort of patients with HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007 , 46, 297-303	3.1	25
47	Treating hepatitis C virus in HIV patients: are side effects a real obstacle?. <i>AIDS Reviews</i> , 2007 , 9, 16-24	1.5	5
46	CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice--clinical implications for CCR5 inhibition as antiretroviral therapy. <i>Hepatology</i> , 2006 , 43, 879; author reply 879-80	11.2	1
45	Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 180-5	3.1	29
44	Natural history of chronic hepatitis B in co-infected patients. <i>Journal of Hepatology</i> , 2006 , 44, S65-70	13.4	163
43	Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. <i>Journal of Hepatology</i> , 2006 , 44, S146-50	13.4	26
42	Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. <i>Antiviral Therapy</i> , 2006 , 11, 567-74	1.6	12
41	Influence of Hepatitis C Genotypes on Lipid Levels in HIV-Positive Patients during Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2006 , 11, 521-527	1.6	7
40	Impact of Lamivudine on the Risk of Liver-Related Death in 2,041 Hbsag- and HIV-Positive Individuals: Results from An Inter-Cohort Analysis. <i>Antiviral Therapy</i> , 2006 , 11, 567-574	1.6	25
39	Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. <i>Aids</i> , 2005 , 19,	3.5	116

38	Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. <i>BMC Infectious Diseases</i> , 2005 , 5, 58	4	27
37	Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naïve HIV-infected individuals. <i>Clinical Infectious Diseases</i> , 2005 , 40, e101-9	11.6	43
36	Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop. <i>AIDS Reviews</i> , 2005 , 7, 161-7	1.5	3
35	Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. <i>Clinical Infectious Diseases</i> , 2004 , 38, 128-33	11.6	249
34	Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. <i>Aids</i> , 2004 , 18, 2285-93	3.5	172
33	A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. <i>Journal of Hepatology</i> , 2004 , 41, 312-8	13.4	6
32	Reply to Bruno et al.. <i>Aids</i> , 2004 , 18, 2102-2103	3.5	
31	Use of Pegylated Interferons is Associated with An Increased Incidence of Infections during Combination Treatment of Chronic Hepatitis C: A Side Effect of Pegylation?. <i>Antiviral Therapy</i> , 2004 , 9, 627-630	1.6	35
30	Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 32, 259-67	3.1	101
29	Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future. <i>Clinical Infectious Diseases</i> , 2003 , 37, 1678-85	11.6	48
28	Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus 'e-minus' patients with YMDD mutations after 4 weeks of tenofovir therapy. <i>Aids</i> , 2003 , 17, 783-4	3.5	22
27	Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C. <i>BMC Infectious Diseases</i> , 2002 , 2, 17	4	
26	HCV chronic hepatitis in patients with HIV: clinical management issues. <i>American Journal of Gastroenterology</i> , 2002 , 97, 1598-606	0.7	20
25	Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naïve HIV-infected subjects. <i>Archives of Internal Medicine</i> , 2002 , 162, 2125-32		174
24	Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 29, 315-7	3.1	24
23	Comment to the editorial: Liver biopsy in HIV-infected patients with chronic hepatitis C: pros and cons, by Vincent Soriano and Javier Garc�a-Samaniego. <i>HIV Clinical Trials</i> , 2002 , 3, 419-20		2
22	Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV. <i>HIV Clinical Trials</i> , 2002 , 3, 324-32		12
21	Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis: an emerging issue. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002 , 30, 535-6	3.1	10

20	Effect of highly active antiretroviral therapy (HAART) and hepatitis C Co-infection on hyperlipidemia in HIV-infected patients: a retrospective longitudinal study. <i>HIV Clinical Trials</i> , 2002 , 3, 451-61		27
19	Histological and virological features and follow-up of hepatitis C virus carriers with normal aminotransferase levels: the Italian prospective study of the asymptomatic C carriers (ISACC). <i>Journal of Hepatology</i> , 2002 , 37, 117-23	13.4	125
18	Hepatitis B virus co-infection in human immunodeficiency virus-infected subjects. <i>AIDS Reviews</i> , 2002 , 4, 27-35	1.5	63
17	Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. <i>British Journal of Haematology</i> , 2001 , 115, 58-62	4.5	127
16	Should lock therapy always be avoided for central venous catheter-associated fungal bloodstream infections?. <i>Clinical Infectious Diseases</i> , 2001 , 33, 1947-8; author reply 1949-51	11.6	31
15	Liver fibrosis progression is related to CD4 cell depletion in patients coinfecting with hepatitis C virus and human immunodeficiency virus. <i>Journal of Infectious Diseases</i> , 2001 , 183, 134-7	7	187
14	Mortality due to chronic viral liver disease among patients infected with human immunodeficiency virus. <i>Clinical Infectious Diseases</i> , 2001 , 33, 1793-5	11.6	34
13	Mortality for Liver Disease in Patients With HIV Infection: A Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000 , 24, 211-217	3.1	82
12	Mortality for liver disease in patients with HIV infection: a cohort study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000 , 24, 211-7	3.1	169
11	Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment. <i>Journal of Infectious Diseases</i> , 2000 , 181, 2033-7	7	56
10	Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. <i>Archives of Internal Medicine</i> , 2000 , 160, 3365-73		79
9	A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. <i>International Journal of Cancer</i> , 1998 , 75, 347-54	7.5	384
8	Prospective study of mother-to-infant transmission of hepatitis C virus (HCV) infection. <i>Journal of Medical Virology</i> , 1998 , 54, 12-19	19.7	46
7	Clonality of B-cells in portal lymphoid infiltrates of HCV-infected livers. <i>Journal of Pathology</i> , 1998 , 185, 86-90	9.4	40
6	Treatment of chronic hepatitis D with interferon alpha-2b in patients with human immunodeficiency virus infection. <i>Journal of Hepatology</i> , 1998 , 29, 45-52	13.4	37
5	Molecular analysis of mixed infection with hepatitis C virus and human immunodeficiency virus in a patient infected simultaneously. <i>Journal of Medical Virology</i> , 1996 , 50, 276-82	19.7	5
4	Differential pattern of sequence heterogeneity in the hepatitis C virus E1 and E2/NS1 proteins. <i>Journal of Hepatology</i> , 1994 , 21, 858-65	13.4	8
3	Evaluation of hepatitis delta virus RNA levels during interferon therapy by analysis of polymerase chain reaction products with a nonradioisotopic hybridization assay. <i>Hepatology</i> , 1992 , 15, 685-9	11.2	26

- 2 Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. *Hepatology*, **1992**, 16, 877-81 11.2 85
- 1 Sequence heterogeneity of the hepatitis C virus envelope region. Implications for the location of predicted antigenic determinants. *Journal of Hepatology*, **1991**, 13 Suppl 4, S38-9 13.4